Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase-Reference-Cited by-同舟云学术

Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase

Published:2013-04-29 Issue:9 Volume:56 Page:3467-3477
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Poplawski Sarah E.¹²,Lai Jack H.¹²,Li Youhua¹,Jin Zhiping¹,Liu Yuxin¹,Wu Wengen¹,Wu Yong¹,Zhou Yuhong¹,Sudmeier James L.¹,Sanford David G.¹²,Bachovchin William W.¹²

Affiliation:

1. Department of Biochemistry, Tufts University Sackler School of Biomedical Sciences, 136 Harrison Avenue, Boston, Massachusetts 02111, United States

2. Arisaph Pharmaceuticals, Inc., 100 High Street, Suite 1202, Boston, Massachusetts 02110, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm400351a

Reference42 articles.

1. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

2. Fibroblast activation protein: Purification, epitope mapping and induction by growth factors

3. Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts

4. Dipeptide Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: Determinants of Potency and in Vivo Efficacy and Safety

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiosynthesis and in-vitro identification of a molecular probe 131I-FAPI targeting cancer-associated fibroblasts;Frontiers in Oncology;2024-08-30

2. Recent Clinical Implications of FAPI;Clinical Nuclear Medicine;2024-07-18

3. 68Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with 18F-FDG;Academic Radiology;2024-06

4. 68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases;Pharmaceutics;2024-04-12

5. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy;European Journal of Medicinal Chemistry;2024-03